Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Lymphoma, B-Cell 2Cholangiocarcinoma 2Biliary Tract Neoplasms 2Recurrence 1Potentially Resectable Locally Advanced Malignant Tumors of Biliary System 1Pancreatic Neoplasms 1Neoplasms 1Lymphoma, Large B-Cell, Diffuse 1Klatskin Tumor 1Cirrhosis, Familial, with Pulmonary Hypertension 1Carcinoma, Transitional Cell 1Carcinoma, Hepatocellular 1Breast Neoplasms 1Adenocarcinoma 1

Interventions

lenvatinib 3Fluorouracil 3Drug Therapy 3Oxaliplatin 2Leucovorin 2Gemcitabine 2Folfox protocol 2Floxuridine 2regorafenib 1gemcitabine-oxaliplatin regimen 1durvalumab 1donafenib 1apatinib 1Surgical Procedures, Operative 1Radiotherapy 1Dexamethasone 1Cryosurgery 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Cirrhosis, Familial, with Pulmonary Hypertension × gemcitabine-oxaliplatin regimen × Clear all
NCT06739252 2026-01-28

Perioperative Treatment of High-risk Resectable CCA With HAIC Plus A+T: Neobrave CCA

Peking University

Phase 2 Terminated
1 enrolled
Gastrointestinal

Cirrhosis, Familial, with Pulmonary Hypertension, Cholangiocarcinoma, Klatskin Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡